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Serum levels of DHEA sulfate are inversely associated with
cardiovascular death in men, and urinary dehydroepi-
androsterone (DHEA) levels are inversely associated with
clinical manifestations of coronary artery disease. These
observations may be related to the antiproliferative effects
of DHEA, resulting in inhibition of atherosclerotic intimal
hyperplasia. To examine the relation between these steroids
and a direct measure of coronary atherosclerosis, plasma
DHEA and DHEA sulfate levels were determined in 206
middle-aged patients 003 men, 103 women) undergoing
elective coronary angiography.
Plasma DHEA sulfate levels were lower in men with at
least one stenosis :2:50% compared with those without any
stenosis :2:50% (4.9 ± 2.7 versus 6.1 ± 3.5 nmoIlml, p =
0.05). Levels of DHEA sulfate were also inversely related to
There is increasing evidence that dehydroepiandrosterone
(DHEA) and its sulfate (DHEA sulfate) may playa role in
the pathogenesis of coronary artery disease. Although these
steroids are major secretory products of the adrenal glands
and the primary constituents of urinary and plasma 17-
ketosteroids. their role in normal physiology has been diffi-
cult to ascertain (1,2). The dramatic age-related decline in
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the number of diseased coronary vessels (r = -0.20, P =
0.05) and a continuous measure of the extent of coronary
atherosclerosis (r =-0.25, p =0.01) in men. The associ-
ation between DHEA sulfate levels and extent of coronary
artery disease was independent of age and other conven-
tional risk factors for coronary disease. In women, there
was no association between plasma DHEA or DHEA sulfate
levels and coronary disease.
These data demonstrate a consistent, independent, in-
verse. dose-response relation between plasma DHEA sul-
fate levels and angiographically defined coronary athero-
sclerosis in men. Plasma DHEA sulfate may be another
important and potentially modifiable risk factor for the
development and progression of coronary atherosclerosis.
(J Am Coil CardioI1990;16:862-70)
urinary (3) and blood (4.5) levels of DHEA and DHEA
sulfate that coincides with the increasing incidence of ather-
osclerosis led several investigators 0.6) to conclude that
these steroids have a protective effect against atherosclero-
sis. Dehydroepiandrosterone has subsequently been shown
to be a potent inhibitor of cell growth. proliferation and
carcinogenesis (1.2). In cell culture, DHEA inhibits fibro-
blast growth (7) and differentiation (8). Because atheroscle-
rosis is characterized by differentiation and proliferation of
smooth muscle cells and fibroblasts (9). these observations
provide a biologically plausible mechanism for a relation
between DHEA levels and coronary disease. Recently. in
two independently conducted studies (10.11), oral adminis-
tration of DHEA provided substantial protection against the
development of aortic atherosclerosis in cholesterol-fed rab-
bits.
Several clinical and population-based studies have dem-
onstrated an inverse relation between the level of DHEA or
DHEA sulfate. or both. and clinical manifestations of coro-
nary atherosclerosis or its risk factors in humans. Five
studies (12-16) have documented low levels of urinary
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17-ketosteroids or plasma DHEA sulfate in patients who had
a prior myocardial infarction (12-15) or a history of heart
disease (16) compared with levels in normal control subjects,
whereas another study (17) demonstrated the opposite re-
sults. One study (12) also identified lower levels of urinary
17-ketosteroids in men with a prior cerebral infarction.
Dehydroepiandrosterone or DHEA sulfate levels, or both,
have been reported to be inversely associated with choles-
terol (18-21), obesity (22,23), diabetes (16) and type A
behavior (24). However, other coronary artery disease risk
factors such as male gender (4,25-27), hypertension (28-30)
and cigarette smoking (16,31,32) have been associated par-
adoxically with elevated levels of plasma or urinary DHEA
sulfate or its metabolites. Barrett-Connor et al. (16,33)
reported an independent inverse association between plasma
DHEA sulfate levels and the subsequent 12 year cardiovas-
cular and ischemic heart disease mortality rate in a prospec-
tive study of 752 men aged 50 to 79 years. In contrast, no
association was found between DHEA sulfate levels and
cardiovascular or ischemic heart disease mortality rates in a
similar cohort of women from the same community (33),
Despite tissue culture, animal model, clinical and popu-
lation-based data suggesting an important relation between
levels of DHEA or DHEA sulfate, or both, and atheroscle-
rosis, there are few data on the relation between these
steroids and a direct measure of atherosclerosis in humans.
In addition, little is known about the relative importance of
plasma levels of DHEA versus DHEA sulfate with respect to
atherosclerosis and the apparent disparity between men and
women in this relation. The importance of understanding the
relation between DHEA and DHEA sulfate levels and cor-
onary atherosclerosis is highlighted by the fact that levels of
these steroids may be raised with physical activity (18,23) or
oral supplementation (20,34).
This report describes the relation between plasma DHEA
and DHEA sulfate levels and angiographically defined cor-
onary atherosclerosis in 206 men and women undergoing
coronary angiography. Detailed information is presented on
the association between DHEA and DHEA sulfate levels,
age, gender and many coronary disease risk factors, as well
as the influence these coronary disease risk factors have on
the DHEA/coronary atherosclerosis association.
Methods
Study patients. Between April 1985 and April 1988, pa-
tients undergoing diagnostic coronary angiography at The
Johns Hopkins Hospital were enrolled in The Johns Hopkins
Coronary Artery Disease Study to examine the relation
between coronary artery disease risk factors and premature
coronary atherosclerosis defined by coronary angiography.
The study design and informed consent procedure were
approved by the Joint Committee on Clinical Investigation of
The Johns Hopkins Medical Institutions on May 14, 1985.
Patients were eligible for enrollment if they were white men
::;50 years of age or white women ::;60 years of age. Other
race groups were not enrolled because anticipated numbers
of such participants were too small to permit meaningful
race-specific subgroup analyses. Patients were not eligible
for enrollment if they lived more than a 3 h drive from
Baltimore, were undergoing emergency coronary angiogra-
phy or percutaneous transluminal coronary angioplasty or
had had a myocardial infarction within the previous 12
weeks. Ninety-one percent of the men and 87% of the
women who were eligible and contacted concerning the
study agreed to participate; 103 men and 103 women were
enrolled over the 3 year period.
Data collection. After informed consent was obtained, a
standardized questionnaire was administered by a trained
interviewer to gather demographic and detailed coronary
artery disease risk factor information, determine medication
use and measure supine blood pressure at rest, height and
weight. The questionnaire included the Rose questionnaire
(35), the Framingham type A personality questionnaire (36)
and the Paffenbarger physical activity questionnaire (37).
The reason for angiography was determined from the cath-
eterization reports for 113 consecutive patients (49 men, 64
women) enrolled after June 13, 1986. Body mass index was
calculated as weight (kg)/height (cm2). On the morning of the
procedure or at the time of angiographic examination, a
fasting blood specimen was obtained; however, the exact
time of day was not recorded. A portion of the plasma was
stored at -70°C for subsequent biochemical analysis.
Coronary angiography. Standard coronary angiography
was performed, including selective engagement of the right
and left coronary arteries and angulated views sufficient to
display the coronary tree completely. Coronary angiograms
were examined by a consensus panel of three physicians
experienced in coronary angiography without knowledge of
patients' risk factor status or DHEA and DHEA sulfate
levels. On a standardized recording form, each of the 15
American Heart Association (AHA) designated coronary
artery segments was characterized as having 0%, 1% to 24%,
25% to 49%, 50% to 74%, 75% to 99% or 100% diameter
stenosis and given a corresponding score of 0 to 5, respec-
tively. Bypass grafts, native vessels proximal to bypass
grafts and poorly visualized segments were not evaluated. A
global measure of the extent of coronary artery disease
(coronary disease score) was calculated as the average score
for all evaluated AHA segments divided by five. The preci-
sion of this coronary disease score was previously estab-
lished (38) using two blinded evaluations of 55 randomly
selected angiograms (r = 0.96, p = 0.001).
The morpholoRY of coronary lesions was recorded by
categorizing each AHA standardized vessel segment as
having no disease, a single focal lesion, multiple discrete
lesions or diffuse or segmental involvement. A correspond-
ing morphology score of ato 3 was assigned to each AHA
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segment and a global morphology score was calculated in a
fashion similar to the coronary disease score (average AHA
segment score divided by three).
Plasma DHEA and DHEA sulfate levels. These were
measured using commercially available radioimmunoassay
kits (Wien Laboratories and Immuchem). These kits were
independently validated with a chromatographic-enzymatic
assay (39). The intra- and interassay variabilities of these
assays were <10% over a range of values that exceeded
those observed in this study. The plasma levels of total
cholesterol and triglycerides and the concentrations of low
density lipoprotein cholesterol and high density lipoprotein
cholesterol were determined using methods of the Lipid
Research Clinics Program (40) as modified by Kwiterovich et
al. (41).
Statistical analysis. The distributions of DHEA and
DHEA sulfate levels were examined using box plots (42).
Two men had extremely high values for both DHEA and
DHEA sulfate (4 to 6 standard deviations above the mean).
One of these men had extensive coronary artery disease and
one had trivial coronary disease; both men were heavy
smokers. The inclusion of these two patients made no
qualitative difference in the associations between DHEA and
DHEA sulfate levels and coronary disease; however, the fit
of the regression models used to describe the data was
markedly improved when they were excluded. The results
presented do not include these two extreme cases.
Age adjustment of DHEA and DHEA sulfate levels was
performed using least squares estimates of marginal mean
values (43), where age was treated as a continuous variable.
The distribution of the coronary artery disease and morphol-
ogy scores deviated significantly from normal; therefore,
Spearmans rank order correlation was used to assess the
univariate association between DHEA and DHEA sulfate
levels and these measures of coronary disease (44). The
coronary disease score was also divided roughly into tertiles.
All patients with totally normal coronary angiograms and
coronary disease scores of zero were assigned to the lowest
tertile. The intermediate tertile (0 < coronary disease score
< 0.25) identified those patients with mild disease, and
coronary disease scores in the highest tertile (coronary
disease score> 0.25) were observed in patients with exten-
sive disease.
Apolycotomous logistic regression technique was used to
examine the relation between DHEA sulfate and coronary
disease score tertiles after adjusting for other variables (45).
Age was treated as a continuous variable. Odds ratios were
calculated from the logistic regression models based on a
decrease of I standard deviation in DHEA or DHEA sulfate
plasma levels. Tests of significance for variables in the
logistic regression model were based on the likelihood ratio
test.
Table 1. Characteristics of the Study Group According to Gender
Men Women
No. 101 103
Median age (yr) 44 52
(range) (24-50) (36-60)
Risk factor
Current smoking (no.)' 81 76
Diabetes mellitus Ino.)t 7 12
Mean systolic blood pressure (mm Hg) 119 121
Mean total cholesterol (mg/dll 225 243
Reason for angiography:!:
Angina or abnormal exercise test. or 67 72
both (%)
Atypical chest pain (%1 12 9
Other ('1m 14 6
Missing or undetermined (%) 6 13
'Within last 6 months; trequiring medication; :!:based on catheterization
reports from 113 (49 men. 64 women) consecutive patients enrolled after June
13. 1986: §congenital or valvular heart disease. dilated cardiomyopathy or
Marfan's syndrome.
Results
Patient characteristics (Table 1). The age difference be-
tween men and women was due to the different age entry
criteria for men and women. Approximately 75% of the
subjects underwent angiography for evaluation of typical
angina or a positive exercise tolerance test, or both.
Distribution of DHEA and DHEA sulfate levels according
to age and gender (Table 2). In men, there was a steady
decline in DHEA and DHEA sulfate levels with increasing
age. Linear regression of DHEA and DHEA sulfate levels
versus age in men predicted an annual decrease in the
DHEA level of 0.53 pmol/ml (r = -0.41, p = 0.0001) and a
yearly decrease in the DHEA sulfate level of 0.21 nmol/ml (r
= -0.35, p = 0.0003). There was no significant association
between age and either steroid level in women, although the
women with the highest levels were in the youngest age
groups.
At ages :::;45 years. men had consistently higher levels of
DHEA and DHEA sulfate than women (Table 2). In the 46 to
50 year age group, there was no difference between DHEA
levels in men and women, although DHEA sulfate levels
were higher in men. Overall. the magnitude of the difference
in DHEA and DHEA sulfate levels between men and women
was greatest in the younger age groups. After adjustment for
age. levels of DHEA sulfate were significantly higher for
men than women (p = 0.002) and there was a nonsignificant
trend toward higher DHEA levels in men.
Association between DHEA and DHEA sulfate levels and
presence of coronary artery disease (Tables 3 and 4). Sixty
percent of the men and 50% of the women had at least one
~50% stenosis of a coronary artery as determined by angi-
ography. Dehydroepiandrosterone sulfate levels were signif-
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Table 2. Dehydroepiandrosterone (DHEAl and Dehydroepiandrosterone Sulfate (DHEAS) Levels
(mean ± SD) in 204 Men and Women Undergoing Diagnostic Coronary Angiography According to
Age Group and Gender
Men Women
Age Group DHEA DHEAS DHEA DHEAS
(yr) No. (pmol/ml) (nmol/mll No. (pmol/mll (nmol/mll
:540 18 19.3 ± 5.2* 7.1 ± 3.6 7 11.5 ± 6.7 4.0 ± 1.7
41-45 41 16.0 ± 7.4 5.5 ± 2.7 13 14.6 ± 9.0 2.6 ± 1.5
46-50 42 11.5 ± 4.8 4.5 ± 2.9 22 11.9 ± 6.8 2.9 ± 1.7
51-55 28 11.4 ± 10.0 2.5 ± 2.6
56-60 33 11.4±9.lt 2.6 ± 2.4
All ages 101 14.7 ± 6.7 5.4 ± 3.1 103 11.9±8.7 2.7 ± 2.2
Age adjusted 14.4+ 5.2§ 13.4+ 3.3§
(:550 yr)
*Based on 17 subjects; tbased on 32 subjects; +p = 0.43 for age-adjusted DHEA levels in men versus women (two
sample t test); §p = 0.0002 for age-adjusted DHEAS levels in men versus women (two sample t test).
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icantly lower in men with at least one :::::50% stenosis (4.9 ±
2.7 versus 6.1 ± 3.5 nmollml, p = 0.05) (Table 3). Dehydro-
epiandrosterone levels were also lower in men with coronary
artery disease defined in this way; however, the difference
was not significant compared with men without at least one
:::::50% stenosis (14.2 ± 6.8 versus 15.4 ± 6.5 pmol/ml, p =
0.40).
Roughly 40% of the men had totally normal-appearing
coronary arteries. Dehydroepiandrosterone sulfate levels
were lower in men with any coronary artery disease, regard-
less of the degree of stenosis, compared with the group with
normal-appearing coronary arteries (4.8 ± 2.6 versus 6.7 ±
3.6 nmollml, p = 0.01). There was also a nonsignificant trend
toward lower DHEA levels in men with any coronary artery
disease (14.0 ± 6.7 versus 16.3 ± 6.5 pmollml, p = 0.13). In
women, there were no differences in DHEA or DHEA
sulfate levels between those with and without any stenosis
:::::50% or those with totally normal coronary arteries com-
pared with those with any stenosis regardless of the degree
of severity.
In men, there was significant, inverse, dose-response
relation between DHEA sulfate levels and the number of
diseased coronary arteries (any stenosis :::::50%) determined
by angiography (Table 4). For DHEA, although mean levels
were higher in men with single vessel disease than in those
with no disease, there remained an overall statistically
significant trend toward lower levels with the increasing
number of diseased vessels. In women, there was no asso-
ciation between DHEA or DHEA sulfate levels and the
number of diseased vessels.
Association between DHEA and DHEA sulfate levels and
coronary artery disease score. Both DHEA and DHEA sul-
fate levels were inversely associated with the extent of
coronary artery disease in men as measured by the coronary
disease score (DHEA: r = -0.26, P = 0.01; DHEA sulfate:
r = -0.25, P = 0.01). Figure 1 shows the mean levels of
DHEA sulfate in men stratified into three age groups and
tertiles of the coronary disease score. Within each age
group, there was a dose-response relation between the mean
level of DHEA sulfate and the extent of coronary disease.
After age adjustment, mean DHEA sulfate levels in men
with extensive disease (highest coronary disease score ter-
tile) remained significantly lower than levels in men with no
disease (lowest coronary disease tertile) (4.9 ± 3.3 versus
6.5 ± 3.0 nmol/m!' p = 0.05). Dehydroepiandrosterone
levels in men with extensive disease were only slightly lower
Table 3. Dehydroepiandrosterone (DHEAl and Dehydroepiandrosterone Sulfate (DHEAS) Levels
(mean ± SD) in 204 Men and Women According to Presence of Angiographically Defined Coronary
Artery Disease* and Gender
Men Women
(n = 101) (n = 103)
DHEA DHEAS DHEA DHEAS
CAD No. (pmol/mll (nmol/mll No. (pmol/mll (nmol/mll
+ 61 14.2 ± 6.8 4.9 ± 2.7 51 12.1 ± 10.lt 2.7 ± 2.5
40 15.4 ± 6.5+ 6.1 ±3.5 52 11.7 ± 7.1 2.8 ± 1.8
p valud 0.40 0.05 0.83 0.80
*Any ~50% diameter stenosis: tbased on 50 participants: +based on 39 participants: §based on two sample t test
for the presence (+) and absence (-) of coronary artery disease (CAD).
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Table 4. Correlation* Between Dehydroepiandrosterone (DHEAj and Dehydroepiandrosterone
Sulfate iDHEASj Levels (mean ± SD) and Number of Diseased Coronary Arteriest in 204 Men
and Women According to Gender
Men Women
No. of (n = 101) (n = 103)
Diseased
Coronary DHEA DHEAS DHEA DHEAS
Arteries No. (pmol/mll (nmol/mll No. (pmol/mll (nmol/ml)
0 40 15.4 ± 6.5+ 6.1 ±3.5 52 11.7 ± 7.It 2.8 ± 1.8
I 15 19.0 ± 9.7 5.5 ± 3.5 13 9.8 ± 8.9 1.5 ± 1.0
2 17 14.1 ± 5.8 5.0 ± 2.2 15 9.7 ± 8.1 2.4 ± 2.0
3 29 11.8 ± 3.9 4.4 ± 2.5 23 15.2 ± 11.5~ 3.5 ± 3.1
r value -0.23 -0.20 -0.04 -0.03
p value 0.02 0.05 0.70 0.78
'Spearman rank order correlation coefficient: t2:507f diameter stenosis: +based on 39 participants: §based on 22
participants.
10
Figure 1. Mean plasma dehydroepiandrosterone sulfate (OHEASj
levels in 98 men according to extent of angiographically defined
coronary atherosclerosis stratified by age group. The age-adjusted
mean level in men with no coronary disease (coronary disease
[CAD) score tertile = I) was significantly higher than that in men
with extensive coronary disease (coronary disease score terti Ie =3)
(6.5 ± 3.0 versus 4.9 ± 3.3 nmoUm!, p = 0.05).
(men: 4.5 ± 2.8 versus 5.7 ± 3.1, p =0.07; women: 2.1 ± 1.3
versus 3.0 ± 2.4. p = 0.01). Similarly. both men and women
with a history of angina had lower levels of DHEA sulfate
(men: 5.0 ± 3.1 versus 6.3 ± 4.3, P =0.09; women: 2.2 ± 1.5
versus 3.0 ± 2.4, P = 0.04).
Association between DHEA sulfate levels and other coro-
nary artery disease risk factors (Table 5). Dehydroepiandros-
terone sulfate levels were 25% to 30% lower in the few men
(n = 7) and women (n = 12) with diabetes; however. this
difference was not statistically significant. Conversely. being
a current smoker and low density lipoprotein cholesterol
levels> 160 mg/dl were both weakly associated with higher
levels of DHEA sulfate in women but not in men. The
association between DHEA sulfate levels and alcohol con-
sumption in women was not maintained after adjustment for
smoking. There was no significant association between
DHEA sulfate levels and systolic or diastolic blood pressure,
total cholesterol. high density lipoprotein cholesterol. tri-
glycerides, body mass index or type A personality score in
either men or women.
Interestingly, in those men who were not current smokers
or diabetic with a systolic blood pressure <160 mm Hg and
a total serum cholesterol <240 mg/dL the association be-
tween low DHEA sulfate levels and coronary artery disease
(any ~50% stenosis) was even stronger than in the entire
group (4.5 ± 2.6 versus 6.4 ± 3.9 nmollml. p = 0.03).
Logistic regression analysis (Table 6). This demonstrated
a significant association between DHEA sulfate levels and
angiographically defined coronary artery disease in men.
After age adjustment, the magnitude of the relative odds of
coronary disease was reduced. but there remained a signif-
icant age-independent association between DHEA sulfate
levels and the relative odds of angiographic coronary dis-
ease. Similar trends were observed for DHEA; however, the
magnitude and significance of the odds ratios were less than
for DHEA sulfate.
To exclude confounding due to other coronary artery
123
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i40
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than in men with no disease after age adjustment (15.1 ± 7.0
versus 15.7 ± 6.4 pmollml, p = 0.77). In women, stratifica-
tion by age group and coronary disease score tertiles re-
vealed no consistent pattern with respect to DHEA or
DHEA sulfate levels.
Association with coronary morphology score, ejection frac-
tion and previous infarction. In addition to the relation to
coronary disease score. DHEA sulfate levels were also
inversely associated with morphology score in men (r =
-0.21, p = 0.06). and men with low DHEA sulfate levels
were also more likely to have a low ejection fraction (r =
0.36. p = 0.(01). In women, there was no association
between DHEA sulfate levels and coronary disease score.
morphology score or ejection fraction. In contrast. both men
and women with a prior myocardial infarction had lower
levels of DHEA sulfate than those without such a history
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Table 5. Age-Adjusted Dehydroepiandrosterone Sulfate (DHEAS) Levels (nmol/mt) in 204 Men and 
Women With or Without Coronary Disease Risk Factors 
Men (n = 101) Women (n = 103) 
Risk Factor Mean ± SD p Value" Mean ± SD p Value 
Current smoker (within last 6 mo.) 
Yes 5.9 ± 2.9 0.43 
3.6 ± 2.1 
0.03 
No 5.3 ± 2J 2.5 ± 2.2 
Diabetes mellitus (requiring medication) 
Yes 3.8 ± 2.9 0.15 
2.1 ± 2.2 
0.26 
No 5.5 ± 2.9 2.8 ± 2.2 
LDL cholesterol >160 mg/dl 
Yes 5.9 ± 2.9 OA6 
3.7 ± 2.2 
0.06 
No 5.3 ± 2.9 2.6 ± 2.1 
History of hypertension 
Yes 5.3 ± 3.1 0.78 
2.9 ± 2.2 
0.37 
No 5.5 ± 2.9 2.5 ± 2.2 
Family history of early CAD 
Yes 5.7 ± 2.9 0.43 
2.9 ± 2.2 
0.48 
No 5.1 ± 2.9 2.6 ± 2.1 
Physical activilyt 
Yes 5.2 ± 2.9 0.46 
2.8 ± 2.2 
0.65 
No 5.6 ± 2.9 2.6 ± 2.2 
Alcohol consumption (within last yr) 
Yes 5.4 ± 2.8 0.93 
3J±2.1 0.006 
No 5.3 ± 2.9 2.1 ± 2.1 
*Basedon two sample I lest: 'sufficient to work up a sweat 2: once a week. CAD = coronary artery disease: 
LDL = low density lipoprotein. 
disease risk factors. the age-adjusted associations between 
DHEA and DHEA sulfate levels and the extent of coronary 
disease were also examined after adjusting individually for 
each of the risk factors discussed in the previous section 
(Table 5). The DHEA sulfate-coronary atherosclerosis re•
lation was also examined after adjusting individually for use 
of nitrates, digoxin or any cardiac medication. The signifi•
cant age-adjusted association between DHEA sulfate levels 
and coronary disease was independent of each of the factors 
tested (p value range 0.04 to 0.0 I). Although the magnitude 
of the age-adjusted odds ratios was smaller for DHEA. it too 
remained significantly associated with the extent of coronary 
Table 6. Relative Odds' and Age-Adjusted Relative Odds of 
AngiographicaUy Defined Coronary Artery Disease for 
Dehydroepiandrosterone (DHEA) and Dehydroepiandrosterone 
Sulfate (DHEAS) Levels in 10\ Men 
DHEA ( t 6.8 pmol/mll 
DHEAS ( t 3.1 nmol/mll 
RO 
1.40 
1.81 
p Valuet 
0.08 
n.003 
With Age 
Adjustment 
RO 
1.15 
1.32 
p Value 
0.04 
0.03 
"Based on logistic regression models of coronary disease score tertiles 
versus a decrease of I standard deviation for DHEA and DHEAS: tp values 
derived from the likelihood ratio chi-square for the effect of D H EA or 
DHEAS. RO = relative odds. 
disease after adjusting individually for each of the factors 
discussed in the previous section (p value range 0.05 to 0.0 I) 
(Table 5). A final model simultaneously adjusting for age, 
smoking. low density lipoprotein cholesterol and diabetes 
continued to demonstrate a significant inverse association 
between DHEA sulfate and the extent of coronary athero•
sclerosis (p = 0.04). 
Discussion 
DHEA plasma level and extent of coronary artery disease. 
These data demonstrate an independent. inverse, dose•
response relation between plasma dehydroepiandrosterone 
(DHEA) sulfate levels and the extent of angiographically 
defined coronary artery disease in men :::;50 years of age 
undergoing clinically indicated diagnostic coronary angiog•
raphy. An association was present between DHEA sulfate 
levels and several different measures of coronary disease 
including any ;:::50% stenosis, any stenosis regardless of 
severity. number of diseased coronary arteries and a global 
measure of coronary disease extent (coronary artery disease 
score). Although the strength of the association between 
DHEA sulfate levels and the extent of coronary disease was 
modest (relative odds ratio 1.8), a significant association was 
maintained after adjustment for age and other coronary 
disease risk factors (relative odds ratio 1.4). In addition, the 
868 HERRINGTON ET AL.
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DHEA sulfate level was inversely associated with several
angiographic and clinical markers of coronary disease sever-
ity, including diffuse lesion morphology, reduced ejection
fraction, history of a prior myocardial infarction and angina.
Similar trends were observed between plasma DHEA
levels and measures of coronary artery disease in men:
however. these trends did not uniformly reach statistical
significance. This may seem counterintuitive because DHEA
is generally viewed as the active metabolite, and DHEA
sulfate is viewed as the chemically stable, storage form of
the steroid. However, it is unclear how plasma levels of
DHEA sulfate may influence tissue levels of DHEA through
the peripherally active sulfatases that can convert DHEA
sulfate to DHEA.
Clinically defined coronary artery disease versus coronary
atherosclerosis. Previous studies (12-16) have documented a
significant association between DHEA sulfate and clinical
manifestations of coronary artery disease; however. clini-
cally defined coronary disease involves a variety of patho-
logic processes in addition to atherosclerotic plaque forma-
tion, such as plaque hemorrhage and rupture. thrombosis of
stenotic lesions and coronary artery spasm (9). Coronary
angiography, unlike clinical diagnosis of coronary disease. is
a direct and specific measure of coronary atherosclerosis.
The observed association in this study between DHEA
sulfate levels and extensive and diffuse coronary disease
supports the hypothesis that DHEA sulfate is related to the
development of coronary atherosclerotic lesions rather than
to the other mechanisms that lead to clinical manifestations
of ischemic heart disease.
DHEA and aging. A portion of the association between
DHEA sulfate levels and extent of coronary artery disease
was accounted for by age. After age adjustment. the odds
ratio for coronary disease associated with a 3.1 nmollml
(I SD) decrease in the DHEA sulfate level decreased from
1.81 to 1.32. It is unclear whether age-related declines in
DHEA and DHEA sulfate levels are simply markers of aging
or whether their decline is part of the physiologic mechanism
through which aging leads to atherosclerosis. If DHEA
sulfate is in the causal chain between aging and atheroscle-
rosis. age adjustment would result in an underestimate of the
strength of the association between DHEA sulfate levels and
coronary disease. However, even if a decline in plasma
DHEA sulfate levels is an epiphenomenon of aging and not
in the aging-atherosclerosis causal chain. there remains a
significant age-independent association between DHEA sul-
fate levels and extent of coronary artery disease. Although
the subjects in this study were relatively young. the results
parallel the findings of Barrett-Connor et at. (16,33) in a
cohort of older men and women.
Gender differences in the relation between DHEA sulfate
levels and coronary atherosclerosis. In women, no relation
between DHEA and DHEA sulfate and angiographic coro-
nary atherosclerosis was found. although women who had
had a prior myocardial infarction had lower levels of both
steroids than those who had not. If the hypothesis is correct
that elevated levels of DHEA or DHEA sulfate, or both,
inhibit atherosclerosis, it is difficult to explain why women
have lower levels of plasma and urinary DHEA and DHEA
sulfate and yet have less atherosclerosis than men. One
possible explanation is that endogenous estrogen or some
other female-specific attribute attenuates the risk of a tow
DHEA or DHEA sulfate level in women. Alternatively, the
beneficial effect of high levels of DHEA or DHEA sulfate in
men may not be due to an antiproliferative effect. but rather
to aromatization of DHEA to estrogen in peripheral tissues.
In this case, women who normally have high levels of
circulating endogenous estrogen would be unlikely to derive
a large additional benefit from conversion of high levels of
DHEA to estrogen.
DHEA and coronary artery disease risk factors. The ob-
served trend toward higher levels of DHEA sulfate in
smokers. especially in women, is consistent with previous
reports (16,3 1,32) and points out the complex relation among
these steroids, coronary disease risk factors and coronary
atherosclerosis. The small number of men and women with
diabetes had age-adjusted DHEA sulfate levels that were
25% to 30% lower than those without diabetes; however.
these differences did not reach statistical significance. De-
hydroepiandrosterone inhibits fat synthesis (8) and increases
tissue insulin sensitivity in mice (46); however. its role in
human diabetes has not been well defined. It is not known
whether low levels of plasma DHEA or DHEA sulfate. or
both. contribute to or are the result of diabetes; however. it
is possible that low levels of these steroids in diabetes is one
of the mechanisms through which diabetes is associated with
coronary artery disease.
Limitations of the current study. There are two major
limitations of this study. First, these are cross-sectional
data: it is possible that a low DHEA sulfate level is a
consequence rather than a cause of coronary atherosclero-
sis. However. the consistency of results from this study with
other prospective population-based data (16) and the anti-
atherogenic effect of DHEA administration in an animal
model of atherosclerosis (10.11) suggest that low plasma
levels of DHEA sulfate are an antecedent to coronary
atherosclerosis. In addition, the similarity of the association
among several different measures of coronary artery disease,
the dose-response relation observed and the fact that the
association belween DHEA sulfate and coronary disease
was independent of age and other risk factors support the
hypothesis that DHEA sulfate is causally related to the
pathogenesis of coronary atherosclerosis.
The second limitation is that the study group is a highly
select olle. Those undergoing coronary angiography are not
representative of the population at large with respect to
traditional coronary artery disease risk factors or symptoms
consistent with coronary disease (47). Because clinicians do
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not check DHEA sulfate levels before deciding to refer a
patient for angiography, a direct referral bias with respect to
DHEA sulfate levels is unlikely. Furthermore, the DHEA
sulfate-coronary disease association was not confounded by
any of the coronary disease risk factors tested or the
presence or absence of angina as defined by the Rose
questionnaire (35). Nevertheless. confounding due to other
unidentified factors remains a possibility.
Patients undergoing elective angiography also are not
representative of all patients with coronary atherosclerosis.
Patients with severe disease resulting in sudden death or
unstable angina requiring emergency angiography were not
studied; however. exclusion of patients with severe disease
would make it more difficult to detect an association between
DHEA or DHEA sulfate levels and coronary atherosclerosis
if the associations hold in these subsets of patients as well. In
general, caution should be used in applying these results to
the general population or assuming that the findings pertain
to all forms of coronary atherosclerosis.
Implications for future investigation of coronary athero-
sclerosis. These data raise the question of whether modify-
ing DHEA sulfate levels could alter the risk of the develop-
ment and progression of atherosclerosis. Some studies
suggest that a low calorie diet (48) or physical activity (18.23)
can result in higher levels of plasma DHEA or DHEA
sulfate. Furthermore. DHEA sulfate levels can be elevated
through oral administration. Two studies have shown that
DHEA (20) or DHEA sulfate (34) can be orally administered
for up to 42 weeks in normal subjects, resulting in significant
increases in plasma DHEA sulfate levels without apparent
adverse side effects. These observations suggest that oral
DHEA could be used to elevate plasma DHEA sulfate levels
safely. However, more observational data. animal models
and information about the bioavailability. pharmacokinetics
and potential side effects of orally administered DHEA are
needed before testing the hypothesis that such an interven-
tion alters the natural history of coronary artery disease in
humans.
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